Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0617089/Asthma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Asthma Therapeutics market. The report identifies the key trends shaping and driving the global Asthma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Asthma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Asthma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Asthma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Asthma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Asthma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Asthma Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Asthma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Asthma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Asthma Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Asthma Therapeutics: Introduction 7
2.1 Disease Overview 7
2.1.1 Epidemiology 7
2.1.2 Classic Signs and Symptoms 9
2.1.3 Etiology 9
2.1.4 Diagnosis 10
2.1.5 Classification 11
2.1.6 Pathogenesis of Asthma 12
2.1.7 Treatment 14
2.1.8 Referral Pathway 16
2.2 GlobalData Pipeline Report Guidance 17
3 Asthma Therapeutics: Market Characterization 18
3.1 Asthma Therapeutics Market Size (2005–2010) – Global 18
3.2 Asthma Therapeutics Market Forecast (2010–2018) – Global 19
3.3 Asthma Therapeutics Market Size (2005–2010) – The US 20
3.4 Asthma Therapeutics Market Forecast (2010–2018) – The US 21
Asthma Therapeutics Market Size (2005–2010) – France 22
3.5 Asthma Therapeutics Market Forecast (2010–2018) – France 23
3.6 Asthma Therapeutics Market Size (2005–2010) – Germany 24
3.7 Asthma Therapeutics Market Forecast (2010–2018) – Germany 25
3.8 Asthma Therapeutics Market Size (2005–2010) – Italy 26
3.9 Asthma Therapeutics Market Forecast (2010–2018) – Italy 27
3.10 Asthma Therapeutics Market Size (2005–2010) – Spain 28
3.11 Asthma Therapeutics Market Forecast (2010–2018) – Spain 29
3.12 Asthma Therapeutics Market Size (2005–2010) – The UK 30
3.13 Asthma Therapeutics Market Forecast (2010–2018) – The UK 31
3.14 Asthma Therapeutics Market Size (2005–2010) – Japan 32
3.15 Asthma Therapeutics Market Forecast (2010–2018) – Japan 33
3.16 Drivers and Barriers for the Asthma Therapeutics Market 34
3.16.1 Drivers for the Asthma Therapeutics Market 34
3.16.2 Barriers for the Asthma Therapeutics Market 34
3.17 Opportunity and Unmet Need Analysis 35
3.18 Key Take away 35
4 Asthma Therapeutics: Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Marketed Product Profiles 37
4.3.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 37
4.3.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 40
4.3.3 Singulair (montekeulast sodium) 41
4.3.4 Foradil (formoterol fumarate inhalation powder) 43
4.3.5 Accolate (zafirlukast) 46
4.3.6 Xolair (omalizumab) 48
4.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder) 49
4.3.8 Dulera/Zenhale (SCH 418131) 51
5 Asthma Therapeutics: Pipeline Assessment 55
5.1 Overview 55
5.2 Strategic Pipeline Assessment 55
5.3 Asthma Therapeutics Pipeline – Pipeline by Phases of Development 56
5.3.1 Asthma Therapeutics – NDA Filed Products 56
5.3.2 Asthma Therapeutics – Phase III Pipeline 57
5.3.3 Asthma Therapeutics – Phase II Pipeline 58
5.3.4 Asthma Therapeutics – Phase I Pipeline 60
5.3.5 Asthma Therapeutics – Pre-Clinical Pipeline 61
5.3.6 Asthma Therapeutics – Discovery Pipeline 62
5.3.7 Technology Trends Analytic Framework 63
5.4 Asthma Therapeutics –Pipeline by Mechanism of Action 65
5.5 Asthma Therapeutics – Promising Drugs under Clinical Development 66
5.6 Molecule Profile for Promising Drugs under Clinical Development 67
5.6.1 Relovair 67
5.6.2 CHF 1535 100/6 NEXT DPI or CHF 1535 pMDI 68
5.6.3 Flutiform (fluticasone proprionate and formoterol fumarate inhalation aerosol) 69
5.6.4 Reslizumab 69
5.6.5 VR315 70
5.6.6 Andolast (CR 2039): 71
5.6.7 KCA-757/MN-001 71
5.6.8 Budesonide-Formoterol Formulation 72
5.6.9 Fluticasone-Salmeterol Formulation 73
5.7 Key Takeaway 73
6 Asthma Therapeutics: Clinical Trials Mapping 74
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 74
6.2 Clinical Trials by Phase 75
6.3 Clinical Trials by Trial Status 76
6.4 Prominent Sponsors 77
6.5 Top Companies Participating in Asthma Therapeutics Clinical Trials 79
7 Strategic Assessment 80
7.1 Key Events Impacting the Future Market 80
7.2 Asthma Therapeutics: Implications for Future Market Competition 81
8 Asthma Therapeutics: Future Players 82
8.1 Introduction 82
8.2 Company Profiles 83
8.2.1 GlaxoSmithKline Plc. 83
8.2.2 Merck & Co., Inc. 86
8.2.3 Novartis AG 88
8.2.4 AstraZeneca 90
8.2.5 Cephalon, Inc. 92
8.2.6 Vectura 94
8.2.7 Orion Corporation 95
8.2.8 Rottapharma SPA 97
8.2.9 SkyePharma PLC 98
9 Asthma Therapeutics: Licensing and Partnership Deals 100
10 Asthma Therapeutics: Appendix 105
10.1 Market Definitions 105
10.2 Abbreviations 105
10.3 Methodology 106
10.3.1 Coverage 106
10.3.2 Secondary Research 107
10.3.3 Forecasting 107
10.3.4 Primary Research 109
10.3.5 Expert Panel Validation 110
10.4 Contact Us 110
10.5 Disclaimer 110
10.6 Bibliography 110
List of Tables
Table 1: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18
Table 2: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19
Table 3: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20
Table 4: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21
Table 5: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22
Table 6: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23
Table 7: Asthma Therapeutics Market, Germany, Forecast ($m), 2005–2010 24
Table 8: Asthma Therapeutics Market, Germany, Forecasts ($m), 2010–2018 25
Table 9: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26
Table 10: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27
Table 11: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28
Table 12: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29
Table 13: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30
Table 14: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31
Table 15: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32
Table 16: Asthma Therapeutics Market, Japan, Forecast ($bn), 2010–2018 33
Table 17: Adverse Reactions With 3% Incidence With Advair Diskus in Adult and Adolescent Patients With Asthma. 38
Table 18: Pooled Data From Three 12-Week, Double-Blind, Placebo-Controlled Clinical Asthma Trials In Patients 12 Years And Older 40
Table 19: Adverse Experiences Occurring in 1% of Patients with an Incidence Greater than that in Patients Treated with Placebo 42
Table 20: Effect of Singulair on Primary and Secondary Endpoints in a Multinational Placebo-Controlled Trial 43
Table 21: Number And Frequency Of Adverse Experiences In Patients From Multiple-Dose Controlled Clinical Trials 44
Table 22: Efficacy Results of Study 40 of Foradil 45
Table 23: Symptom and Rescue Medication Use (Adults with Asthma) 45
Table 24: A Comparison of Adverse Events Reported by 1% of Zafirlukast-Treated Patients 47
Table 25: Mean Change from Baseline at Study End Point 47
Table 26: Adverse Reaction Incidence in Two 12-Week Clinical Trials in Adult and Adolescent Patients With Asthma 50
Table 27: Study Design of Phase III trial 53
Table 28: Clinical Trial with Dulera 100 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction In Lung Function 53
Table 29: Clinical Trial With Dulera 200 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction in Lung Function 54
Table 30: Asthma Therapeutics, NDA Filed Products, 2011 56
Table 31: Asthma Therapeutics, Phase III Pipeline, 2011 57
Table 32: Asthma Therapeutics, Phase II Pipeline, 2011 58
Table 33: Asthma Therapeutics, Phase I Pipeline, 2011 60
Table 34: Asthma Therapeutics, Pre-Clinical Pipeline, 2011 61
Table 35: Asthma Therapeutics, Discovery Pipeline, 2011 62
Table 36: Asthma Therapeutics – Most Promising Drugs Under Clinical Development, 2011 66
Table 37:Study Details of CHF 1535 100/6 NEXT DPI 69
Table 38: Asthma Therapeutics, Clinical Trials by Country, 2011 74
Table 39: Asthma Therapeutics – Clinical Trials by Phase, 2011 75
Table 40: Asthma Therapeutics, Clinical Trials by Status , 2011 76
Table 41: Asthma Therapeutics, Prominent Sponsors, 2011 78
Table 42: Asthma Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 79
Table 43: GSK – Respiratory and Immuno-inflamation Pipeline Products, 2011 85
Table 44: GSK –Asthma Pipeline Products, 2011 85
Table 45: Merck & Co., Inc. – Respiratory Pipeline, 2011 87
Table 46: Merck & Co., Inc. – Asthma pipeline, 2011 88
Table 47: Novartis AG – Respiratory pipeline 89
Table 48: Novartis AG – Asthma Pipeline 89
Table 49: AstraZeneca – Respiratory Pipeline Products, 2011 91
Table 50: AstraZeneca – Asthma Pipeline Products, 2011 91
Table 51: Orion Corporation – Respiratory Pipeline, 2011 96
Table 52: Orion Corporation – Respiratory Pipeline, 2011 97
Table 53: Asthma Therapeutics, Global, Deals, 2009-2011 100
List of Figures
Figure 1: Asthma Prevalence Control Extrapolated to The European Union Population (in millions) 8
Figure 2: Asthma Etiology Hypothesis With Common Triggers 10
Figure 3: Classification of Asthma Control 11
Figure 4: T lymphocytes in Allergic Asthma 12
Figure 5: Phases of Asthmatic Attack. 13
Figure 6: Treatment Of Chronic asthma 15
Figure 7: Asthma Referral Pathway 16
Figure 8: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18
Figure 9: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19
Figure 10: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20
Figure 11: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21
Figure 12: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22
Figure 13: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23
Figure 14: Asthma Therapeutics Market, Germany, Revenue ($m), 2005–2010 24
Figure 15: Asthma Therapeutics Market, Germany, Forecast ($m), 2010–2018 25
Figure 16: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26
Figure 17: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27
Figure 18: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28
Figure 19: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29
Figure 20: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30
Figure 21: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31
Figure 22: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32
Figure 23: Asthma Therapeutics Market, Japan, Forecast ($m), 2010–2018 33
Figure 24: Opportunity and Unmet Need in the Asthma Therapeutics Market, 2010 35
Figure 25: Asthma Therapeutics, Strategic Competitor Assessment, 2010 36
Figure 26: Asthma Therapeutics, Molecular Structure of Zenhale 52
Figure 27: Asthma Therapeutics – Pipeline by Phase of Development, 2011 56
Figure 28: Asthma Therapeutics, Technology Trends Analytics Framework, 2011 63
Figure 29: Asthma Therapeutics, Technology Trends Analytics Framework, Description, 2011 64
Figure 30: Asthma Therapeutics, Pipeline by Mechanism of Action (%), 2011 65
Figure 31: Asthma Therapeutics, Molecular Structure of Relovair 67
Figure 32: Asthma Therapeutics, Molecular Structure of Foster 68
Figure 33: Structure of Andolast 71
Figure 34: KCA 757/MN001 Structure 72
Figure 35: Asthma Therapeutics, Clinical Trials by Country, 2011 74
Figure 36: Asthma Therapeutics, Clinical Trials by Phase (%), 2011 75
Figure 37: Asthma Therapeutics, Clinical Trials by Status (%), 2011 76
Figure 38: Asthma Therapeutics, Overall Sponsors (%), 2011 77
Figure 39: Asthma Therapeutics, Prominent Sponsors (%), 2011 78
Figure 40: Asthma Therapeutics, Top Companies Participating in Clinical Trials, 2011 79
Figure 41: Asthma Therapeutics Market, Drivers and Restraints, 2011 80
Figure 42: Implications for Future Market Competition in the Asthma Market, 2011 81
Figure 43: Asthma Therapeutics Market, Pipeline by Company, 2011 82
Figure 44: GlobalData Market Forecasting Model 109
Companies Mentioned
GlaxoSmithKline Plc.
Merck & Co., Inc.
Novartis AG
AstraZeneca
Cephalon, Inc.
Vectura
Orion Corporation
Rottapharma SPA
SkyePharma PLC
To order this report:
Pathology Industry: Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article